Find a clinical trial

FindClinicalTrial

If you have questions about clinical trials or want help finding the right one for you, contact our:

Patient Engagement Center Phone: 844-552-2734

This is a preliminary search of all open and enrolling clinical trials across our regions and affiliate organizations that have sponsors' permission to publish to this website.

Please use the filtering options in the right column to refine your search. Otherwise ALL open and enrolling clinical trials will display below.

« Previous 12345 Next »
Viewing Page 1 of 19 | Showing Results 1 - 5 of 92

A PHASE IIA, MULTI-CENTER, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF A SINGLE INTRAVENOUS DOSE OF ALLOGENEIC HUMAN MESENCHYMAL STEM CELLS TO SUBJECTS WITH MILD TO MODERATE DEMENTIA DUE TO ALZHEIMER’S DISEASE

This is a Phase IIa multi-center, randomized, single-blind, placebo-controlled, crossover study insubjects with mild to moderate dementia due to...

Santosh Kesari, M.D.
  • John Wayne Cancer Institute (JWCI)
  • Providence St. Johns Health Center (PSJHC)

A Randomized, Controlled, Open-label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients with Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC) (ATLAS)

This is a global, randomized, controlled, open-label phase 3 study of UGN-102 with or without TURBT vs. TURBT alone in the treatment of patients...

Jennifer Linehan, M.D.
  • John Wayne Cancer Institute (JWCI)

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer

This is a Phase 3, multicenter, randomized, parallel group, open-label, controlled trial of the combination of cabozantinib (40 mg po qd) with...

Przemyslaw Twardowski
  • John Wayne Cancer Institute (JWCI)
  • Providence St. Johns Health Center (PSJHC)

An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer.

This is a global phase 3 open-label, 3-arm randomized multicenter study to evaluate the combination of enfortumab vedotin + pembrolizumab, with or...

Przemyslaw Twardowski
  • John Wayne Cancer Institute (JWCI)
  • Providence St. Johns Health Center (PSJHC)
« Previous 12345 Next »
Viewing Page 1 of 19 | Showing Results 1 - 5 of 92